Back to top
more

Vir Biotechnology (VIR)

(Delayed Data from NSDQ)

$7.63 USD

7.63
901,240

-0.41 (-5.10%)

Updated Apr 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VIR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Vir Biotechnology, Inc. [VIR]

Reports for Purchase

Showing records 1 - 20 ( 49 total )

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/15/2024

Company Report

Pages: 7

Key Takeaway From Biotech Breakthroughs HBV Event

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/23/2024

Company Report

Pages: 8

4Q23 Results; Potential Best-in-Class Regimens in Viral Hepatitis B and D Poised to Shine in 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/14/2024

Company Report

Pages: 8

Positioned For Leadership in the Coming Hepatitis B Breakthrough Boom; Upping Price Target to $110; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/23/2024

Company Report

Pages: 11

HDV and HBV Programs on Track For Key Phase 2 Readouts in 2024 and 2025; Modulating Price Target to $85; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/14/2023

Company Report

Pages: 6

Announces Cost Optimization to Drive $40M Annual Savings; HBV Program on Track for Phase 2 Readouts in 2024; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for VIR 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/14/2023

Company Report

Pages: 8

Vaccinal Effect Could Explain the Unprecedented Functional Cure Rates at 24 Weeks; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/10/2023

Daily Note

Pages: 3

HBV Program on Track For Potentially Unprecedented Functional Cure Rates; HDV Program Impresses; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/07/2023

Company Report

Pages: 9

3Q23 Results; Nearing Phase 2 Data Readouts in HBV and HDV

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/31/2023

Company Report

Pages: 8

HBV Conference Takeaways: Expect Compelling Phase 2 Combination Regimen Data at AASLD in November

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/19/2023

Industry Report

Pages: 14

Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/07/2023

Company Report

Pages: 10

Bright Spotlight on Phase 2 Data in Chronic HBV Program in 4Q23; Lowering PT to $95 on Flu False Start; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/20/2023

Daily Note

Pages: 3

PENINSULA Disappoints; Next Gen Flu Program Emerges; Spotlight Shifts to HBV Program Updates Expected in 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

06/28/2023

Company Report

Pages: 9

Evidence Building in Favor of VIR-2218 Plus VIR-3434 Combination as Functional Cure For Chronic HBV

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/09/2023

Company Report

Pages: 10

1Q23 Results; Pipeline Progressing; Crucial Near- Term HBV and Influenza Phase 2 Data Readouts on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/06/2023

Company Report

Pages: 10

4Q22 Results; HBV, Flu, and HIV Programs Take Center Stage as COVID-19 Exits; Lowering Price Target to $100; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

02/07/2023

Daily Note

Pages: 110

HCW 2023 Top Picks: Seize the Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/29/2022

Company Report

Pages: 14

Data Updates on Programs Targeting HBV, Influenza, and COVID-19 Poised to Turn 2023 Into a Pivotal Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/11/2022

Company Report

Pages: 9

2Q22 Results; XEVUDY Path Forward Focused on Ex-U.S. Markets; Broad Infectious Disease Pipeline Progressing

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

07/14/2022

Company Report

Pages: 10

Brii Opts in to VIR-3434, Providing Another Path to a Potential $50B-Plus HBV Cure Market in China; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party